Biohaven Financial Statements From 2010 to 2024

BHVN Stock  USD 46.01  0.47  1.01%   
Biohaven Pharmaceutical financial statements provide useful quarterly and yearly information to potential Biohaven Pharmaceutical Holding investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Biohaven Pharmaceutical financial statements helps investors assess Biohaven Pharmaceutical's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Biohaven Pharmaceutical's valuation are summarized below:
Market Capitalization
4.7 B
Earnings Share
(9.37)
We have found one hundred twenty available fundamental signals for Biohaven Pharmaceutical Holding, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Biohaven Pharmaceutical's prevailing fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road. As of the 3rd of December 2024, Enterprise Value is likely to grow to about 3 B
Check Biohaven Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biohaven Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.3 M, Interest Expense of 1.2 M or Selling General Administrative of 60.1 M, as well as many indicators such as Price To Sales Ratio of 0.46, Dividend Yield of 0.0 or PTB Ratio of 7.48. Biohaven financial statements analysis is a perfect complement when working with Biohaven Pharmaceutical Valuation or Volatility modules.
  
Check out the analysis of Biohaven Pharmaceutical Correlation against competitors.

Biohaven Pharmaceutical Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets347.2 M513.2 M239 M
Slightly volatile
Other Current Liabilities32.1 M36.5 M18 M
Slightly volatile
Total Current Liabilities49.1 M55.4 M28.5 M
Slightly volatile
Property Plant And Equipment Net51 M48.6 M14.5 M
Slightly volatile
Accounts Payable10 M15.6 M7.1 M
Slightly volatile
Cash151.3 M248.4 M159.7 M
Slightly volatile
Non Current Assets Total40.6 M70.8 M24.7 M
Slightly volatile
Non Currrent Assets Other4.2 M2.4 M6.4 M
Slightly volatile
Cash And Short Term Investments270 M381.8 M193.9 M
Slightly volatile
Common Stock Shares Outstanding53.5 M71.2 M48.9 M
Pretty Stable
Liabilities And Stockholders Equity347.2 M513.2 M239 M
Slightly volatile
Non Current Liabilities Total55.3 M29.8 M38.5 M
Pretty Stable
Other Current Assets49.7 M47.4 M15.7 M
Slightly volatile
Other Stockholder Equity73.8 M39.8 M47.2 M
Slightly volatile
Total Liabilities91 M85.2 M66.1 M
Slightly volatile
Total Current Assets306.6 M442.4 M214.3 M
Slightly volatile
Common Stock970.6 M887.5 M621.6 M
Slightly volatile
Short and Long Term Debt Total29.3 M30.9 M154 M
Pretty Stable
Other Liabilities2.6 M2.8 M2.1 M
Slightly volatile
Other Assets0.951.01.1 M
Very volatile
Net Receivables13 M13.6 M93.6 M
Slightly volatile
Short Term Investments161.9 M133.4 M213.6 M
Slightly volatile
Net Invested Capital280 M428 M97.7 M
Slightly volatile
Property Plant And Equipment Gross41.5 M56.9 M23 M
Slightly volatile
Non Current Liabilities Other2.1 M2.2 M43.1 M
Pretty Stable
Net Working Capital274.1 M387 M124.6 M
Slightly volatile
Short Term DebtM3.3 M1.1 M
Slightly volatile
Intangible Assets18.9 M16.6 M33.5 M
Slightly volatile
Property Plant Equipment63 M60 M22.6 M
Slightly volatile
Warrants48 M54 M58.8 M
Slightly volatile
Long Term Debt501.4 M564 M614.2 M
Slightly volatile
Common Stock Total Equity1.3 B1.5 B1.6 B
Slightly volatile
Long Term Debt Total501.4 M564 M614.2 M
Slightly volatile
Capital Surpluse135.7 M152.7 M166.3 M
Slightly volatile
Capital Lease Obligations23.6 M30.9 M7.9 M
Slightly volatile
Deferred Long Term Liabilities10.5 M11.8 M12.8 M
Slightly volatile

Biohaven Pharmaceutical Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization7.3 M6.9 M1.2 M
Slightly volatile
Interest Expense1.2 M1.2 M14.3 M
Very volatile
Selling General Administrative60.1 M56.9 M109.7 M
Slightly volatile
Other Operating Expenses399.6 M436.1 M435.2 M
Slightly volatile
Research Development315.7 M373.3 M323.5 M
Pretty Stable
Total Operating Expenses399.6 M436.1 M435.2 M
Slightly volatile
Cost Of Revenue3.2 M3.4 M6.7 M
Pretty Stable
Reconciled Depreciation7.3 M6.9 M1.2 M
Slightly volatile
Selling And Marketing Expenses4.7 M5.3 M5.8 M
Slightly volatile

Biohaven Pharmaceutical Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation27.3 M28.8 M34.8 M
Slightly volatile
Begin Period Cash Flow130.8 M242.6 M75.2 M
Slightly volatile
Other Non Cash Items15.3 M16.1 M25.5 M
Slightly volatile
Capital Expenditures2.9 MM4.1 M
Slightly volatile
Total Cash From Financing Activities354.4 M211.9 M271.8 M
Slightly volatile
End Period Cash Flow215.1 M252.1 M166.9 M
Slightly volatile
Depreciation7.3 M6.9 M1.2 M
Slightly volatile
Change To Netincome362 M344.8 M100.4 M
Slightly volatile
Change To Liabilities6.5 M6.8 M9.3 M
Slightly volatile
Sale Purchase Of Stock276.5 M311.1 M338.7 M
Slightly volatile
Net Borrowings336.4 M378.4 M412 M
Slightly volatile
Cash And Cash Equivalents Changes32.2 M36.3 M39.5 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.460.510.5547
Slightly volatile
Days Sales Outstanding6.267.047.6653
Slightly volatile
Stock Based Compensation To Revenue0.110.130.139
Slightly volatile
Capex To Depreciation0.420.44129.5474
Slightly volatile
EV To Sales1.411.581.7212
Slightly volatile
Payables Turnover0.210.21631.336
Pretty Stable
Sales General And Administrative To Revenue0.06470.07280.0793
Slightly volatile
Research And Ddevelopement To Revenue0.310.350.3841
Slightly volatile
Capex To Revenue0.00160.00180.002
Slightly volatile
Cash Per Share8.445.36267.0371
Slightly volatile
Interest Coverage30.1533.9236.939
Slightly volatile
Days Payables Outstanding1.6 K1.7 K10.7 K
Slightly volatile
Income Quality0.770.81270.7282
Pretty Stable
Intangibles To Total Assets0.03660.03860.2734
Slightly volatile
Current Ratio8.367.983110.8656
Slightly volatile
Receivables Turnover37.3442.045.7334
Slightly volatile
Graham Number17.6127.844312.1884
Slightly volatile
Debt To Equity15.0614.346.6774
Slightly volatile
Capex Per Share0.04070.04280.1084
Slightly volatile
Revenue Per Share10.3311.6212.653
Slightly volatile
Debt To Assets1.122.161.1015
Slightly volatile
Days Of Payables Outstanding1.6 K1.7 K10.7 K
Slightly volatile
Ebt Per Ebit1.110.93921.0725
Slightly volatile
Long Term Debt To Capitalization0.550.850.6069
Slightly volatile
Total Debt To Capitalization0.550.850.6069
Slightly volatile
Debt Equity Ratio15.0614.346.6774
Slightly volatile
Quick Ratio8.027.990210.7029
Slightly volatile
Net Income Per E B T1.10.99661.0079
Slightly volatile
Cash Ratio6.854.48199.8694
Slightly volatile
Days Of Sales Outstanding6.267.047.6653
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.821.00921.0055
Pretty Stable
Fixed Asset Turnover20.322.8324.8609
Slightly volatile
Debt Ratio1.122.161.1015
Slightly volatile
Price Sales Ratio0.460.510.5547
Slightly volatile
Asset Turnover2.612.933.1909
Slightly volatile
Gross Profit Margin0.640.720.7856
Slightly volatile
Operating Cycle27.7131.1733.9431
Slightly volatile
Cash Conversion Cycle12.514.0615.3098
Slightly volatile

Biohaven Pharmaceutical Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.2 BB667.1 M
Slightly volatile
Enterprise ValueB2.8 B798.1 M
Slightly volatile

Biohaven Fundamental Market Drivers

Cash And Short Term Investments381.8 M

Biohaven Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Biohaven Pharmaceutical Financial Statements

Biohaven Pharmaceutical investors utilize fundamental indicators, such as revenue or net income, to predict how Biohaven Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-34.4 M-32.7 M
Cost Of Revenue3.4 M3.2 M
Stock Based Compensation To Revenue 0.13  0.11 
Sales General And Administrative To Revenue 0.07  0.06 
Research And Ddevelopement To Revenue 0.35  0.31 
Revenue Per Share 11.62  10.33 
Ebit Per Revenue(0.43)(0.45)

Pair Trading with Biohaven Pharmaceutical

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biohaven Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biohaven Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.

Moving against Biohaven Stock

  0.88VCNX VaccinexPairCorr
  0.46DRMA Dermata TherapeuticsPairCorr
  0.45VALN Valneva SE ADRPairCorr
  0.34ME 23Andme HoldingPairCorr
The ability to find closely correlated positions to Biohaven Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biohaven Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biohaven Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biohaven Pharmaceutical Holding to buy it.
The correlation of Biohaven Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biohaven Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biohaven Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biohaven Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Biohaven Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biohaven Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biohaven Pharmaceutical Holding Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biohaven Pharmaceutical Holding Stock:
Check out the analysis of Biohaven Pharmaceutical Correlation against competitors.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(9.37)
Return On Assets
(1.19)
Return On Equity
(2.65)
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.